COMMUNIQUÉS West-GlobeNewswire

InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in China
28/05/2026
BEIJING, May 28, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for [...]
ViCentra Scales Commercial Manufacturing, Triples Capacity and Strengthens Unit Economics
28/05/2026
Commercial-scale production of Kaleido consumables begins at contract manufacturer Phillips Medisize Manufacturing capacity more than triples, with initial capacity to support over 17,000 users Volume manufacturing [...]
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
28/05/2026
THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stroma-rich tumours US trial (OCTOPOD-IP) is exploring [...]
XL‑protein Launches Spin-Off PASylANTA Therapeutics to Develop Long‑Acting IL‑1Ra Biobetters
28/05/2026
Freising, Germany, May 28, 2026 (GLOBE NEWSWIRE) -- XL‑protein GmbH today announced the launch of PASylANTA Therapeutics GmbH , a new Germany-based biotechnology company focused on the development of long‑acting IL‑1 [...]
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
28/05/2026
Orphan Drug Designation confers regulatory, financial and strategic advantages EO2463 has shown potentially disease modifying activity in clinical testing in watch-and-wait iNHL patients EO2463 has shown complementary [...]
Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
28/05/2026
Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3 Paris, le 28 mai 2026. L’Agence américaine des produits alimentaires et médicamenteux ( [...]
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
28/05/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
28/05/2026
Les données concernant IQIRVO ® viennent enrichir les connaissances scientifiques sur la fatigue, en montrant des améliorations cliniquement significatives chez des patients présentant une fatigue modérée à sévère à l’ [...]
argenx to Host Myositis R&D Webinar on June 23, 2026
28/05/2026
May 28, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will [...]
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
28/05/2026
IQIRVO ® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1 [...]
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
28/05/2026
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) [...]
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
28/05/2026
UK and US trial sites open; first patient dosed with TGX-007, Trogenix’s proprietary dual-payload AAV gene therapy TGX-007 leverages Trogenix’s precision synthetic super-enhancer platform that selectively activates [...]
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
28/05/2026
Transactions Provide Financial Flexibility to Advance Pipeline of Next Generation Cancer Therapies Comprised of Novel Bispecific T-cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs) Support Closing of Business [...]
BioNature Berberine Claims Evaluated: Premium Berberine AMPK Activator Supplement for Blood Sugar & Metabolism Support
28/05/2026
Two-Product Berberine and Chromium Picolinate Protocol for AMPK Support, Insulin Sensitivity, and Healthy Blood Sugar Levels Explained Miami, FL, May 27, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
Memora Supplement Under Investigation: Effective Brain Booster Formula Against EMF Radiation - Latest Memory Health Report
28/05/2026
Bacopa Monnieri, Lion's Mane, and Ginkgo Biloba Cognitive Formula - Ingredients, Side Effects, Complaints, and Refund Policy Explained New York, NY, May 27, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living [...]
Sana Biotechnology to Present at June 2026 Investor Conferences
27/05/2026
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations [...]
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
27/05/2026
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
27/05/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

Pages